Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Harvard Business School
Express Scripts
Citi
Dow
Baxter
Chubb
Johnson and Johnson
Medtronic

Generated: November 13, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021615

« Back to Dashboard

NDA 021615 describes RAZADYNE ER, which is a drug marketed by Janssen Pharms and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug and two Paragraph IV challenges. Additional details are available on the RAZADYNE ER profile page.

The generic ingredient in RAZADYNE ER is galantamine hydrobromide. There are fifteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the galantamine hydrobromide profile page.
Summary for 021615
Tradename:RAZADYNE ER
Applicant:Janssen Pharms
Ingredient:galantamine hydrobromide
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 021615
Mechanism of ActionCholinesterase Inhibitors
Medical Subject Heading (MeSH) Categories for 021615
Suppliers and Packaging for NDA: 021615
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615 NDA Patriot Pharmaceuticals, LLC 10147-0891 10147-0891-3 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (10147-0891-3)
RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615 NDA Patriot Pharmaceuticals, LLC 10147-0892 10147-0892-3 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (10147-0892-3)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 8MG BASE
Approval Date:Apr 1, 2005TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Dec 20, 2019Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 16MG BASE
Approval Date:Apr 1, 2005TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Dec 20, 2019Product Flag?YSubstance Flag?Delist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 24MG BASE
Approval Date:Apr 1, 2005TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Dec 20, 2019Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 021615

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615-001 Apr 1, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Janssen Pharms RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615-003 Apr 1, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Janssen Pharms RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615-002 Apr 1, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
AstraZeneca
Baxter
Farmers Insurance
QuintilesIMS
US Department of Justice
Healthtrust
US Army
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.